Trial ID or NCT#

NCT03028740

Status

recruiting iconRECRUITING

Purpose

The AURORA study will be conducted to confirm the efficacy and safety of cenicriviroc (CVC) for the treatment of liver fibrosis in adult subjects with NASH.

Official Title

AURORA: A Phase 3 Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis

Eligibility Criteria

Ages Eligible for Study: 18 Years to 75 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Paul Kwo
Paul Kwo
Hepatologist, Transplant hepatologist
Professor of Medicine (Gastroenterology and Hepatology)

Contact us to find out if this trial is right for you.

CONTACT

Swati Toppo
650.497.4151